WallStSmart
PTHS

Pelthos Therapeutics Inc.

NYSE MKT: PTHS · HEALTHCARE · BIOTECHNOLOGY

$25.09
+0.48% today

Updated 2026-04-29

Market cap
$83.79M
P/E ratio
P/S ratio
4.99x
EPS (TTM)
$-23.04
Dividend yield
52W range
$9 – $38
Volume
0.0M

WallStSmart proprietary scores

23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
5.0
Quality
C+
2.0
Profitability
F
4.7
Valuation
C
/9
Piotroski F-Score
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target
$57.14
+127.74%
12-Month target
Intrinsic (DCF)
$21.47
Margin of safety
-2.75%
1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
Insufficient data
Risks
- Thin margins at -257.90%
- Negative free cash flow $-6.35M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$16.80M$16.80M
Net income$-2.46M$-7.38M$-7.96M$-43.32M$-21.66M
EPS$-23.04
Free cash flow$-1.57M$-981031.00$-5.79M$-22.69M$-6.35M
Profit margin-257.93%-257.90%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
PTHS$83.79M234.32.04.75.0-2.75%Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$322.34B545.35.57.34.8+42.06%Buy
AZN$294.17B646.78.05.35.0+4.07%Buy

Smart narrative

Pelthos Therapeutics Inc. trades at $25.09. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $16.80M. with profit margins at -257.90%. Our DCF model estimates intrinsic value at $21.47.

Frequently asked questions

What is Pelthos Therapeutics Inc.'s stock price?
Pelthos Therapeutics Inc. (PTHS) trades at $25.09.
Is Pelthos Therapeutics Inc. overvalued?
Smart Value Score 23/100 (Grade F, Strong Sell). DCF value $21.47.
What is the price target of Pelthos Therapeutics Inc. (PTHS)?
The analyst target price is $57.14, representing +127.7% upside from the current price of $25.09.
What is the intrinsic value of Pelthos Therapeutics Inc. (PTHS)?
Based on our DCF model, intrinsic value is $21.47, a -2.8% margin of safety versus $25.09.
What is Pelthos Therapeutics Inc.'s revenue?
TTM revenue is $16.80M.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE MKT
CurrencyUSD

Quick metrics

P/S ratio4.99x
ROE-239.60%
Beta3.99
50D MA$22.90
200D MA$25.64
Shares out0.00B
Float0.00B
Short ratio
Avg volume0.0M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years